Bhatt was just 26 when she was diagnosed with polycystic kidney disease (PKD)—a condition she discovered by chance while ...

DelveInsight's Polycystic Kidney Disease Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Polycystic Kidney Disease treatment.

ADPKD, a prevalent genetic disorder characterized by the growth of numerous kidney cysts, affects about 1 in 400 to 1,000 people worldwide. The disease progressively impairs kidney function, often ...

The transaction was approved by both companies' boards and includes a significant premium over recent stock prices for ...

Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 ...

Basel: Novartis has announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. With the ...

Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed ...

Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal.

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus"). With ...

Novartis has announced the expiration of its tender offer to acquire Regulus Therapeutics Inc., marking a significant step ...

ADPKD is a common inherited form of kidney disease. It is caused by flaws in specific genes (PKD1 or PKD2), leading to numerous cysts growing in the kidneys, which can eventually cause kidney failure.